All News

Previewing executive trends thought of by leaders in the pharma industry.

AI-powered platform can transform medical expert and opinion leader engagement planning for medical affairs teams.

Pharmaceutical R&D industry report provides insights into what’s behind decline in global NME outputs and reveals implications of decreased projected expenditures.

Women’s leadership and mentoring initiatives garner Healthcare Businesswomen’s Association top honors for BD, GSK, Surgical Care Affiliates, and Walgreens Boots Alliance.

Theme for this year's virtual event is delivering digital impact at scale.

A technology-enabled solution combining predictive analytics integrated with real-time commercial services for the life sciences sector.

In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.

Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?

Review platform launches in light of new research which reveals that 93% lack trust in pharma companies.

COVID-19 has only magnified well known flaws of our healthcare system. An extension of Medicare is the affordable solution, writes Bruno Delagneau, and pharma needs to start planning for this to minimize its impact on US revenues.

Dr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.

W2O, today announced findings from a research study on consumer attitudes toward data privacy, specifically personal health data.

How “Contractual Genericization” could revitalize pharma and reframe the public conversation.

IQVIA has announced the launch of OCE Optimizer, which will look to help life sciences companies reach HCPs more effectively.

Gilead's pricing of COVID drug remdesivir is a reminder of pharma's tenuous path forward as it seeks a more holistic image makeover.

While scientists are striving to discover and produce safe and effective vaccines to halt the coronovirus outbreak, anti-vacciners are revving up misinformation campaigns.